BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

Preclinical publications highlighted in BioCentury’s Distillery this year identified white space target opportunities including untapped E3 ubiquitin ligases, vesicular regulators and ion channels, as...
BioCentury | Nov 23, 2020
Product Development

Immunocore charts the path for bispecifics in solid tumors with Phase III readout

...antigens. GSK101, which targets NY-ESO-1 and is partnered with GlaxoSmithKline plc (NYSE:GSK; LSE:GSK), IMC-C103C targeting MAGEA4...
BioCentury | Oct 27, 2020
Distillery Therapeutics

PCF11 binding site on E3 ubiquitin ligase MAGEA11 identified as neuroblastoma target

DISEASE CATEGORY: Cancer INDICATION: Neuroendocrine tumors Interrupting the interaction between the oncogenic E3 ubiquitin ligase MAGEA11 and its substrate PCF11 could treat neuroendocrine tumors. Crystallographic analysis of the MAGEA11-PCF11 complex identified a shallow cleft on...
BioCentury | Aug 6, 2020
Emerging Company Profile

T-knife: creating TCR factories with transgenic mice

Armed with a €66 million ($78.2 million) series A round, T-knife emerged from stealth Thursday with plans to bring four TCR therapies into clinical testing by 2022 using a transgenic mouse platform designed to generate...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

...ErbB2) (neu) Erb-b2 receptor tyrosine kinase 3 (HER3) (ERBB3) (EGFR3) Interleukin-13 (IL-13) receptor alpha 2 (IL-13RA2) (IL-13R) (CD213A2) Melanoma-associated antigen A4 (MAGEA4) Mesothelin Mucin...
BioCentury | Jan 13, 2020
Clinical News

Adaptimmune rises on early promise for SPEAR TCR cell therapies in solid tumors

...also targets MAGEA4, but also expresses the CD8α co-receptor. Targets - AFP - Alpha fetoprotein; MAGEA4...
BioCentury | Sep 13, 2019
Emerging Company Profile

Valo: adding tumor antigens to oncolytic viruses

With platforms that can rapidly display tumor-specific antigens on oncolytic viruses without genetic engineering, Valo is positioning itself as an attractive collaborator for immuno-oncology companies. Oncolytic viruses kill cancer cells by lysing the cells, and...
BioCentury | Aug 22, 2019
Emerging Company Profile

Tscan: Tracking down novel T cell targets

...companies developing TCR therapies include Adaptimmune, which has three programs against known TCR targets MAGEA10, MAGEA4...
...Targets AFP - Alpha fetoprotein TTN - Titin MAGEA3 - Melanoma-associated antigen A3 MAGEA4 - Melanoma-associated antigen A4...
BioCentury | Aug 8, 2019
Tools & Techniques

Checkpoint inhibitors are bringing oncolytic viruses back into the spotlight

Early clinical readouts for next-generation oncolytic viruses are hinting at high efficacy when combined with checkpoint inhibitors, and pharmas are off to the races to find the best pairings. After more than two decades of...
BioCentury | Aug 2, 2019
Clinical News

Aug. 2 Clinical Quick Takes: AB Sciences halts metastatic melanoma program; plus NIH, Adaptimmune and more

...Writer MAGE A10 TCR, MAGE-A10 SPEAR T-cell therapy (MAGEA10 TCR) MAGE A4 TCR, MAGE-A4 SPEAR T-cell therapy, MAGEA4...
...AB1010, masican, masipro) TJD5 AB Science S.A. Adaptimmune Therapeutics plc I-Mab Biopharma Kiyatec Inc. NIH Tracon Pharmaceuticals Inc. Ecto-5'-nucleotidase (CD73) (NT5E) Melanoma-associated antigen A10 (MAGEA10) Melanoma-associated antigen A4 (MAGEA4) RSV...
Items per page:
1 - 10 of 94